Anika Therapeutics, Inc.

Anika is headquartered in the United States and manufactures its global commercial supply from a single site in Bedford, Massachusetts. The U.S. is the most important operating market because it combines direct sales for regenerative products with OEM supply relationships for core OA products. Outside the U.S., the company relies on a worldwide distributor network to commercialize products in local markets, which reduces the need for a large direct-sales footprint but increases partner dependence. International sales growth was specifically cited as a driver of commercial channel growth in 2024, showing that non-U.S. markets matter to the growth strategy. Geography is operationally important because manufacturing concentration in one U.S. facility creates supply-chain and regulatory exposure, while international markets depend on local partner execution and reimbursement conditions.

Anika is exposed to concentration risk because a single customer, J&J MedTech, represented 50% of revenue in 2025, so any change in purchasing, pricing, or channel strategy could materially affect results. The company also relies on a single manufacturing site in Bedford, Massachusetts, which creates operational risk from equipment failure, quality issues, regulatory interruptions, or natural disasters. Competitive pressure is significant because orthopedic and OA pain products face established rivals, pricing pressure from hospitals and group purchasing organizations, and reimbursement-driven cost containment. Regulatory risk is meaningful because product approvals, labeling requirements, and compliance obligations can delay launches or restrict market access, especially for products like Hyalofast. In addition, product liability claims, inventory reserves, and dependence on third-party distributors can affect margins and cash flow when demand or channel execution weakens.